Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Shahani

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Blood Advances|October 7, 2021
Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 daysLekha Mikkilineni, Bonnie Yates, Seth M Steinberg, et al.
Journal for Immunotherapy of Cancer|November 28, 2020
Diagnostic approach to the evaluation of myeloid malignancies following CAR T-cell therapy in B-cell acute lymphoblastic leukemiaGeorge Mo, Hao-Wei Wang, Aimee C Talleur, et al.
Blood Advances|January 30, 2025
Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucelFrederick L Locke, Tanya Siddiqi, Caron A Jacobson, et al.
American Journal of Hematology|March 20, 2024
Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapyMatthew A Lunning, Hai-Lin Wang, Zhen-Huan Hu, et al.
Journal for Immunotherapy of Cancer|June 4, 2021
Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastomaErin F Simonds, Edbert D Lu, Oscar Badillo, et al.
The New England Journal of Medicine|June 5, 2023
Survival with Axicabtagene Ciloleucel in Large B-Cell LymphomaJason R Westin, Olalekan O Oluwole, Marie José Kersten, et al.
Blood|May 23, 2022
CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CARHaneen Shalabi, Haiying Qin, Angela Su, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Blood Advances|October 7, 2021
Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 daysLekha Mikkilineni, Bonnie Yates, Seth M Steinberg, et al.
Journal for Immunotherapy of Cancer|November 28, 2020
Diagnostic approach to the evaluation of myeloid malignancies following CAR T-cell therapy in B-cell acute lymphoblastic leukemiaGeorge Mo, Hao-Wei Wang, Aimee C Talleur, et al.
Blood Advances|January 30, 2025
Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucelFrederick L Locke, Tanya Siddiqi, Caron A Jacobson, et al.
American Journal of Hematology|March 20, 2024
Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapyMatthew A Lunning, Hai-Lin Wang, Zhen-Huan Hu, et al.
Journal for Immunotherapy of Cancer|June 4, 2021
Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastomaErin F Simonds, Edbert D Lu, Oscar Badillo, et al.
The New England Journal of Medicine|June 5, 2023
Survival with Axicabtagene Ciloleucel in Large B-Cell LymphomaJason R Westin, Olalekan O Oluwole, Marie José Kersten, et al.
Blood|May 23, 2022
CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CARHaneen Shalabi, Haiying Qin, Angela Su, et al.
Pageof 2